ShoreTel Inc. (SHOR) Drops 5.46% on December 23

Equities Staff |

ShoreTel Inc. (SHOR) was one of the Russell 2000's biggest losers for Wednesday December 23 as the stock slid 5.46% to $8.93, a loss of $-0.515 per share. Starting at an opening price of $9.45 a share, the stock traded between $8.83 and $9.46 over the course of the trading day. Volume was 1.3 million shares over 6,133 trades, against an average daily volume of 476,881 shares and a total float of 65.59 million.

The losses send ShoreTel Inc. down to a market cap of $585.41 million. In the last year, ShoreTel Inc. has traded between $10.56 and $6.49, and its 50-day SMA is currently $9.57 and 200-day SMA is $7.71.

ShoreTel Inc along with its subsidiaries is engaged in providing business communication solutions, including; integrated voice, video, data and mobile applications based on Internet Protocol (IP) technologies.

ShoreTel Inc. is based out of Sunnyvale, CA and has some 1,063 employees. Its CEO is Donald Joos.

For a complete fundamental analysis analysis of ShoreTel Inc., check out Equities.com’s Stock Valuation Analysis report for SHOR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

GoCoin

Blockchain currencies (e.g. Bitcoin) provide a new disruptive way to transfer value between parties over the internet as opposed to going through banks. GoCoin provides online merchants with a suite…

Lyft

Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…